Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07167446 · ClinicalTrials.gov registry record · Early Phase 1

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

A Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC), sponsored by Fox Chase Cancer Center.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT07167446 is a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC) that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 30 participants, below the 56-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07167446, a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Fox Chase Cancer Center.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.

Conditions Studied

Peripheral Neuropathy Due to Chemotherapy Metastatic Colorectal Cancer (CRC) Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients

Interventions

  • DRUG Cannabidiol (CBD)
  • DRUG oxaliplatin-based chemotherapy

Study Locations (1)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-10-14
Est. Completion 2028-09-07
Phase Early Phase 1

Sponsor

Fox Chase Cancer Center

183 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07167446

The ClinicalTrials.gov registry entry for NCT07167446 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 56-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (46% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 2 interventions - of which Cannabidiol (CBD) is the first listed.

NCT07167446 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07167446 about?

NCT07167446 is a clinical study titled "Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy". This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Pa...

What is the current status of trial NCT07167446?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-10-14. Estimated completion is 2028-09-07.

What conditions does trial NCT07167446 study?

This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy, Metastatic Colorectal Cancer (CRC), Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients.

What interventions are being tested in trial NCT07167446?

The interventions under investigation include: Cannabidiol (CBD) (DRUG), oxaliplatin-based chemotherapy (DRUG).

Who is sponsoring clinical trial NCT07167446?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07167446 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peripheral Neuropathy Due to Chemotherapy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Peripheral Neuropathy Due to Chemotherapy

All registered trials for this condition

Metastatic Colorectal Cancer (CRC)

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.